GAITHERSBURG, Md. – Jan. 19, 2022 – Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today ...
Nuvaxovid™ is the first protein-based COVID-19 vaccine available for use in adolescents aged 12 through 17 in Australia GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a ...
(RTTNews) - Novavax, Inc. (NVAX) announced the Australian Therapeutic Goods Administration has granted provisional registration of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine as a booster in individuals ...
In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history GAITHERSBURG, Md., June 13, 2022 /PRNewswire/ -- Novavax, ...
Vasso Apostolopoulos COVID-19 research has received internal funding from Victoria University place-based Planetary Health research grant and from philanthropic donations. Jack Feehan does not work ...
Nov 4 (Reuters) - Novavax Inc (NVAX.O), opens new tab said on Wednesday it has signed an agreement with the Australian government to supply 40 million doses of its COVID-19 vaccine candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback